Press release
Hepatocellular Carcinoma Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight
"Hepatocellular Carcinoma Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hepatocellular Carcinoma Market.
The Hepatocellular Carcinoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Hepatocellular Carcinoma Pipeline Report: https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Hepatocellular Carcinoma treatment therapies with a considerable amount of success over the years.
• Hepatocellular Carcinoma companies working in the treatment market are Saronic Biotechnology, HiFiBiO Therapeutics, Sirnaomics, Exelixis, Tvardi Therapeutics, Portage Biotech Inc., MoAMiNA Therapeutics Limited, SOTIO Biotech Inc., Surface Oncology, Virogin Biotech Ltd., Innovent Biologics, Beijing ShenogenPharmaceutical Technology Co., Ltd, Can-Fite, CStone Pharmaceuticals, H 3 Biomedicine Inc, Genoscience Pharma, Kymab Limited, Exelixis, and others, are developing therapies for the Hepatocellular Carcinoma treatment
• Emerging Hepatocellular Carcinoma therapies in the different phases of clinical trials are- SBI 1997, HFB-301001, STP 705, XL092, TTI-101, PORT-7, MTL-CEBPA, SOT101, SRF388, VG161, IBI310, Icaritin, Namodenoson(CF102), CS1003, H3B-6527, GNS561, KY1044, Cabozantinib, and others are expected to have a significant impact on the Hepatocellular Carcinoma market in the coming years.
• In February 2025, The FDA granted fast track designation to RZ-001, an RNA substitution enzyme-based cancer gene therapy, for the treatment of patients with hepatocellular carcinoma (HCC), according to an announcement from Rznomics Inc. Additionally, RZ-001 has received investigational new drug approval for glioblastoma (GBM) from both the FDA and South Korea's Ministry of Food and Drug Safety, and it has been approved for compassionate use under the FDA's expanded access program for this condition.
• In January 2025, Tempest Therapeutics announced that the US Food and Drug Administration has granted Orphan Drug Designation to amezalpat (TPST-1120), an oral, small molecule, selective PPAR⍺ antagonist for the treatment of patients with hepatocellular carcinoma.
• In November 2024, Carisma Therapeutics announced the presentation of new pre-clinical data on its antiGPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for the treatment of hepatocellular carcinoma, developed in collaboration with Moderna, Inc. (Nasdaq: MRNA).
• In October 2024, NAYA Biosciences ("NAYA") (NASDAQ: NAYA), a life science portfolio company focused on delivering breakthrough treatments in oncology, autoimmune diseases, and fertility, today provided an update on its clinical trial plans. The company received regulatory approval from the Israeli Ministry of Health in July 2024, followed by institutional review board clearance to begin patient enrollment in up to seven academic centers. The clinical trial will assess the safety and efficacy of NY-303, its GPC3-targeting NK Engager bispecific antibody, as a monotherapy for treating hepatocellular carcinoma in patients who have not responded to first-line immunotherapy.
• In August 2024, Myeloid Therapeutics administered the first dose in a Phase I clinical trial evaluating MT-303 for hepatocellular carcinoma (HCC). This open-label, dose-escalation study aims to assess the pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy of MT-303 in adults with advanced or metastatic HCC that overexpresses GPC3. Additionally, the trial will establish the recommended Phase II dose (RP2D) for further development.
• In February 2024, Iterion Therapeutics, a biopharmaceutical company specializing in oncology, is actively enrolling patients in a Phase 1b/2a clinical trial for its lead candidate, tegavivint. The trial targets individuals with advanced hepatocellular carcinoma (HCC) who have not responded to at least one prior systemic therapy. Tegavivint is a small molecule inhibitor of Transducin beta-like protein 1 (TBL1), a key downstream target in the Wnt/beta-catenin signaling pathway.
Hepatocellular Carcinoma Overview
In primary liver cancer, hepatocellular carcinoma (HCC) is the most prevalent kind. People with chronic liver illnesses, such as cirrhosis brought on by hepatitis B or hepatitis C infection, are most frequently affected by hepatocellular carcinoma. An important stage in the viral carcinogenesis of hepatocellular carcinoma is cirrhosis.
Get a Free Sample PDF Report to know more about Hepatocellular Carcinoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Hepatocellular Carcinoma Drugs Under Different Phases of Clinical Development Include:
• SBI 1997: Saronic Biotechnology
• HFB-301001: HiFiBiO Therapeutics
• STP 705: Sirnaomics
• XL092: Exelixis
• TTI-101: Tvardi Therapeutics
• PORT-7: Portage Biotech Inc.
• MTL-CEBPA: MoAMiNA Therapeutics Limited
• SOT101: SOTIO Biotech Inc.
• SRF388: Surface Oncology
• VG161: Virogin Biotech Ltd.
• IBI310: Innovent Biologics
• Icaritin: Beijing ShenogenPharmaceutical Technology Co., Ltd
• Namodenoson(CF102): Can-Fite
• CS1003: CStone Pharmaceuticals
• H 3 Biomedicine Inc: H3B-6527
• Genoscience Pharma: GNS561
• Kymab Limited: KY1044
• Exelixis : Cabozantinib
Hepatocellular Carcinoma Route of Administration
Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Hepatocellular Carcinoma Molecule Type
Hepatocellular Carcinoma Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Hepatocellular Carcinoma Pipeline Therapeutics Assessment
• Hepatocellular Carcinoma Assessment by Product Type
• Hepatocellular Carcinoma By Stage and Product Type
• Hepatocellular Carcinoma Assessment by Route of Administration
• Hepatocellular Carcinoma By Stage and Route of Administration
• Hepatocellular Carcinoma Assessment by Molecule Type
• Hepatocellular Carcinoma by Stage and Molecule Type
DelveInsight's Hepatocellular Carcinoma Report covers around 95+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Hepatocellular Carcinoma product details are provided in the report. Download the Hepatocellular Carcinoma pipeline report to learn more about the emerging Hepatocellular Carcinoma therapies
https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Hepatocellular Carcinoma Therapeutics Market include:
Key companies developing therapies for Hepatocellular Carcinoma are - H3 Biomedicine Inc, Genoscience Pharma, Kymab Limited, Exelixis, CStone Pharmaceuticals, TaiRx, Yiviva, AVEO Oncology, Eureka Therapeutics, Shanghai Henlius Biotech, Innovent Biologics, Akesobio, BeiGene, Zai Lab (Shanghai) Co, Geneos Therapeutics, Adaptimmune Therapeutics, and others.
Hepatocellular Carcinoma Pipeline Analysis:
The Hepatocellular Carcinoma pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma Treatment.
• Hepatocellular Carcinoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatocellular Carcinoma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Hepatocellular Carcinoma drugs and therapies
https://www.delveinsight.com/sample-request/hepatocellular-carcinoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Hepatocellular Carcinoma Pipeline Market Drivers
• The Rise in the Incidence of Hepatocellular Carcinoma, Increasing Research and Developmental Activities are some of the important factors that are fueling the Hepatocellular Carcinoma Market.
Hepatocellular Carcinoma Pipeline Market Barriers
• However, poor quality of care, hepatic complications related to hepatocellular carcinoma, morbidity Related to the Disease and other factors are creating obstacles in the Hepatocellular Carcinoma Market growth.
Scope of Hepatocellular Carcinoma Pipeline Drug Insight
• Coverage: Global
• Key Hepatocellular Carcinoma Companies: Saronic Biotechnology, HiFiBiO Therapeutics, Sirnaomics, Exelixis, Tvardi Therapeutics, Portage Biotech Inc., MoAMiNA Therapeutics Limited, SOTIO Biotech Inc., Surface Oncology, Virogin Biotech Ltd., Innovent Biologics, Beijing ShenogenPharmaceutical Technology Co., Ltd, Can-Fite, CStone Pharmaceuticals, H 3 Biomedicine Inc, Genoscience Pharma, Kymab Limited, Exelixis, and others
• Key Hepatocellular Carcinoma Therapies: SBI 1997, HFB-301001, STP 705, XL092, TTI-101, PORT-7, MTL-CEBPA, SOT101, SRF388, VG161, IBI310, Icaritin, Namodenoson(CF102), CS1003, H3B-6527, GNS561, KY1044, Cabozantinib, and others
• Hepatocellular Carcinoma Therapeutic Assessment: Hepatocellular Carcinoma current marketed and Hepatocellular Carcinoma emerging therapies
• Hepatocellular Carcinoma Market Dynamics: Hepatocellular Carcinoma market drivers and Hepatocellular Carcinoma market barriers
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatocellular Carcinoma Pipeline 2025: Key Developments, Emerging Therapies, and Clinical Trials Detailed Analysis by DelveInsight here
News-ID: 4187023 • Views: …
More Releases from DelveInsight Business Research
Global Patient Flow Management Solutions Market to was valued USD 1,555.65 milli …
According to DelveInsight's analysis, The growing need for patient flow management solutions is largely fueled by the increasing number of chronic conditions such as diabetes and cardiovascular diseases, which require continuous care and monitoring. The move toward more patient-focused healthcare, along with technological advancements and the introduction of innovative products, is further boosting market expansion. Moreover, government-backed initiatives promoting digital health adoption are playing a key role in supporting the…
Global Orphan Drugs Market to reach USD 357.26 billion growing at a CAGR of 6.98 …
According to DelveInsight's analysis, The orphan drugs market is seeing strong expansion, largely due to the increasing number of rare and genetic diseases worldwide and the significant unmet need for effective treatments. Since many rare conditions still lack approved therapies, the market presents major growth potential. Supportive government regulations-such as incentives, market exclusivity, and faster approval processes-are also encouraging more companies to invest in orphan drug development by lowering financial…
Global Antidote Market to reach USD 4,007.09 million growing at a CAGR of 7.13% …
According to DelveInsight's analysis, The antidote market is expanding rapidly, largely due to the growing cases of poisoning, drug overdoses, and increased incidents of snake and animal bites. This rising demand is supported by greater public health awareness, government programs aimed at overdose prevention and treatment, and continuous advancements in antidote development. Moreover, new product launches and innovations by major industry players addressing toxic exposures are further strengthening market growth.…
Global Artificial Intelligence In Drug Discovery Market to grow at a CAGR of 37. …
According to DelveInsight's analysis, The AI in drug discovery market is experiencing strong growth due to the increasing global burden of diseases, the benefits AI brings to pharmaceutical development, and rising investments in R&D. Additionally, growing collaborations and strategic partnerships between public and private organizations, both domestically and internationally, are expected to further accelerate market expansion throughout the 2025-2032 forecast period.
DelveInsight's "Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape…
More Releases for Hepatocellular
Laboratory-Produced Molecule In The Hepatocellular Carcinoma Drugs Market Indust …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Hepatocellular Carcinoma Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for drugs used in hepatocellular carcinoma has seen significant expansion in the past few years. The market, which is predicted to rise from $1.16 billion in 2024 to $1.27 billion in…
Rising Occurrence Of Hepatocellular Carcinoma Fuels Growth In The Hepatocellular …
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hepatocellular Carcinoma Drugs Market Size During the Forecast Period?
The Hepatocellular Carcinoma Drugs Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025…
Hepatocellular Carcinoma Pipeline 2024
DelveInsight, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Request a sample and discover the recent…
Hepatocellular Carcinoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Hepatocellular Carcinoma Pipeline Insight 2024" report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Hepatocellular…
Hepatocellular Carcinoma Market - Winning the Battle Against Hepatocellular: Bre …
Newark, New Castle, USA: The "Hepatocellular Carcinoma Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hepatocellular Carcinoma Market: https://www.growthplusreports.com/report/hepatocellular-carcinoma-market/8027
This latest report researches the industry structure, sales, revenue,…
Hepatocellular Carcinoma Market Insights, Forecast to 2030
The report extensively examines the global Hepatocellular Carcinoma market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Hepatocellular Carcinoma . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the global market…
